Expression Of HGFK1 In Hepabocellular Carcinoma And Its Clinical Significance

Background:Malignant tumor growth, invasion and the metastasis of cancer is currently the focus of academic study, recent studies confirmed the formation of new blood vessels in tumor growth and metastasis plays a key role[1-2]. Therefore, inhibition of tumor angiogenesis can inhibit tumor growth and metastasis. The so-called anti-angiogenesis gene therapy is to get the angiogenesis regulatory factor gene into the tumor or target cell's surrounding tissue, by changing the balance of the tumor angiogenesis factor and inhibitory factor to achieve the purpose of treatment of cancer. Currently gene therapy against tumor angiogenesis mainly through the following three ways:(1)Reduced the expression of angiogenic factors promote; (2)induced angiogenesis inhibitory factor production; (3)interfere with the signal transmission between cells, the kringle 1 domain of human hepatocyte growth factor, HGFK1), as a new anti-angiogenic molecules, is becoming the new darling of the study of the Current cancer gene therapy. But reports on the relationship between HGFK1 and liver cancer is relatively few, and inconsistent in some respects the views. Objective:The expression of HGFK1 in human hepatocellula carcinoma was investigated to explore the relationship of invasion, metastatic of human hepatocellula carcinoma, and prognosis of patients with human hepatocellula carcinoma to HGFK1 expression.Method:Specimens were taken from 58 human hepatocellula carcinoma tissues from Taizhou Hospital. These specimens were obtained from the patients who underwent hepatotomy from January 2002 to March 2005.44 cases were male and 14 females, aged 29～72 years, mean 54.68 years. All cases were confirmed by pathological examination of hepatocellular carcinoma. Hepatoma cell differentiation: well differentiated 24 cases (Edmondson gradeⅠ～Ⅱlevel),34 cases of poorly differentiated (Edmondson grade III-IV level). Pathological diagnosis confirmed 16 cases of portal thrombosis,42 cases of no portal thrombosis. According to 3-year recurrence:32 cases of recurrence,26 cases of no recurrence. Calculated 5-year survival rate. Survival time from counting on postoperative day 1, the deadline for the May 30,2010,SP immunohistochemistry was used to evaluate the expression of HGFK1 in 58 human hepatocellula carcinoma tissues.Results:In poorly differentiated group, HGFK1 high expression in 7 cases, High expression rate is 20.1%(7/34) in high differentiation group, HGFK1 high expression in 14 cases, High expression rate is 58.3%(14/24); the high expression rate of HGFK1 between the 2 groups is significant difference (P<0.01); in portal vein tumor thrombus formation group, HGFK1 high expression in 4 cases, High expression rate is 25%(4/16); in no portal vein tumor thrombus formation group, HGFK1 high expression in 24 cases, high expression rate is 57.1%(24/42). the high expression rate of HGFK1 between the 2 groups is significant difference (P<0.05); in 3-year recurrence group, HGFK1 high expression in 9 cases, high expression rate is 28.1%(9/32), while in the 3-year without recurrence group, HGFK1 high expression in 19 cases, high expression rate is 73.1%(19/26), the high expression rate of HGFKl between the 2 groups is significant difference (P<0.05); the patient with HGFK1 high expression's 5 year survival rate is 43.5%, the patient with HGFKl low expression's 5 year survival rate is 16.7%, significantly different between the two (P<0.05).Conclusion:The HGFKl expression is associated with pathological grade of HCC and portal vein tumor thrombus formation,and has not related with age, sex, preoperative AFP level, tumor size and clinical characteristics. The HGFKl expression may be involve in the occurrencer and development and transfer of liver cance, can be used as an important prognostic indicator in patients with liver cancer.